Little information is currently available on the outcome and the long-term restoration of immune function in infants with combined immunodeficiency and residual T cells (T þ CID) treated by BMT. We prospectively followed patients with T þ CID who received matched unrelated donor BMT at our center. Engraftment, immune reconstitution and transplant-related complications were recorded. Humoral and cellular immunity were evaluated. Ten patients with combined immune deficiency who had more than 1000 circulating T cells/ll were designated as having T þ CID. They were diagnosed at a mean age of 9.7 months and received a matched unrelated donor BMT at the mean age of 17.4 months. All 10 patients are alive and well at a mean of 110 months after transplant. All patients have evidence of full hemopoietic engraftment and robust immune function. We have shown here that matched unrelated donor BMT is highly effective in curing patients with T þ CID. This mode of treatment should be preferred for patients with T þ CID when a related identical donor is not available.
Introduction
Severe combined immune deficiency (SCID) is a heterogeneous group of inherited diseases characterized by significantly impaired immunity leading to death in infancy unless treated by hematopoietic stem cell transplantation. The optimal treatment for patients with SCID is BMT from a related HLA-identical donor. Unfortunately, such donors are found only for a minority of patients with SCID. 1 As an alternative, SCTs from HLA-mismatched related donors (MMRDs) have been commonly attempted. 2 Compiled experience of BMT for SCID from Europe revealed that in 294 recipients of MMRD BMT, 3-year survival was only 54%. 3 Furthermore, in another study, careful analysis of survival, according to the degree of HLA identity, showed that frank haploidentical (half-matched) transplantation resulted in only 25-30% long-term survival in patients with primary immunodeficiency. 4 This low success rate may reflect the intense T-cell depletion required to prevent GVHD, which contributes to slower immune reconstitution with prolonged periods of increased susceptibility to infections. 5 Recent studies have suggested a time-dependent loss of function following T-cell-depleted MMRD BMT, associated with progressive lymphopenia, a restricted T-cell repertoire, decreased thymic output as indicated by reduced levels of TCR excision circles and abnormal humoral immunity. 6 A substantial number of SCID patients may present with a significant number of circulating autologous T cells with variable degrees of cell-mediated function. In recent years, patients with mutations in Jak-3, Zap-70, IL-2Ra and CD3 were reported to have autologous T cells and/or residual T-cell function, commonly referred to as T þ CID. [7] [8] [9] [10] Moreover, even patients with X-linked SCID, such as those with the R222C mutation, may present as T þ CID. 11, 12 Such patients present with near-normal or normal numbers of circulating T cells and responses to mitogens as well as having normal thymus morphology. 13 Omenn's syndrome related or unrelated to cartilage hair hypoplasia as well as 'partial' ADA deficiency may also present with residual T-cell function. [14] [15] [16] Experience with the application of BMT to patients with CID who have residual function has been extremely limited. Among T þ CID patients transplanted with T-cell-depleted BM, engraftment rates have been poor, ranging from 14 to 30%, and short-term survival rates reached 47%, but long-term survival as low as 12.5% has been recorded. 17, 18 These discouraging results point to a pressing need for better transplant alternatives to ensure a full engraftment and reconstitution of immunological function and a better long-term survival rate.
We prospectively enrolled infants and children with T þ CID who had no sibling donor into a protocol using matched unrelated donor (MUD) transplantation in an attempt to improve survival and reduce morbidity in these patients.
Methods

Patients
Ten consecutive patients with T þ CID, diagnosed in the Division of Immunology at the Hospital for Sick Children (Toronto, Canada) between December 1989 and June 2005, were enrolled in this study. Diagnosis was based on clinical findings, family history and immune evaluation. In some patients, the diagnosis required histological assessment of the thymus and the ability to reject an allogenic skin graft. T þ CID was defined based on (1) lack of maternally engrafted cells, (2) normal lymphocyte count and (3) CD3 þ T-lymphocyte counts of more than 1000 cells/ml. In all patients, HIV was excluded by PCR. Patients who lacked histocompatible siblings or closely matched related donors received MUD BMT. Data were collected until May 2007, so that all children had a minimum follow-up of 12 months after BMT.
HLA typing and donor selection
Until 1993, lymphocytes were tested for HLA A, B, C and DR typing using standard serological methods. Since 1993, Class II histocompatibility was further analyzed by DNA hybridization with sequence-specific oligonucleotide probes. 19 Since 1999, both Class I and II histocompatibilities were analyzed solely by molecular techniques.
Transplantation procedures
From diagnosis until discharge, patients were treated in laminar airflow units. Trimethoprim/sulfametaxozole or pentamidine was used for Pneumocystis jiroveci prophylaxis. Intravenous Igs (600 mg/kg) were infused to maintain IgG levels above 6 g/l. Acyclovir (1500 mg/m 2 /day) was administered to patients who received BM from CMV seropositive donors. All blood products were CMV negative and irradiated. Pretransplant conditioning therapy consisted of BU (4 mg/kg/day) given over 4 days, followed by a 4-day course of CY (50 mg/kg/day) as described previously. The severity of GVHD was graded according to Glucksberg et al. 20 Chronic GVHD was defined if it presented or occurred more than 100 days after transplant, although symptoms were often similar to acute GVHD. GVHD prophylaxis, administered to all patients from the day prior to transplant, consisted of CsA combined with methylprednisolone and/or MTX. All patients were infused with nondepleted 3-5 Â 10 8 donor BM mononuclear cells per kg of recipient weight. Patients received GM-CSF or G-CSF from the day of transplant until the ANC was 41.0 Â 10 9 /l for 3 consecutive days.
Engraftment and chimerism studies Neutrophil engraftment was considered to have occurred on the first of 3 consecutive days in which the absolute neutrophil count exceeded 0.5 Â 10 9 /l. Platelet engraftment was considered to have occurred on the first day of 7 consecutive days in which the platelet count exceeded 20 Â 10 9 /l without platelet transfusion. Whole blood was analyzed for long-term donor engraftment as described previously. 19 Where a sex difference existed between donor and recipient, DNA was analyzed using a Y-specific probe (ZFX/ZFY) to confirm donor lymphocyte engraftment. In the absence of sex difference, RFLP analyses were performed by studying genetic polymorphism, which are due to a variable number of tandem repeats or (CA)n in varying regions in the genome.
Lymphocyte markers and T-cell proliferative responses
Cell surface markers of peripheral blood cells, using immunofluorescent Abs (Beckman-Coulter Diagnostics, Mississauga, Ontario, Canada) and flow cytometry (Epics V; Coulter Electronics, Hialeah, FL, USA) and lymphocyte proliferation in response to PHA stimulation, using tritiated thymidine incorporation, were determined as described previously. 8, 9, [11] [12] [13] [14] [15] 19 For lymphocyte proliferation studies, cells were harvested after 3 days and samples counted in a liquid scintillation counter. All assays were performed in triplicate and stimulation index was calculated as the ratio between stimulated and nonstimulated lymphocyte responses and compared with stimulation index obtained from controls. Serum concentrations of Igs were measured using nephelometry. Levels of serum Abs to tetanus were measured by ELISA and polio Ab titers were determined by complement fixation. 8, 9, [11] [12] [13] [14] [15] 19 Quantification of TCR excision circles The amount of signal joint TCR excision circles adjusted to CD4
þ and CD8 þ T-cell subsets was determined by real-time quantitative PCR, as described previously. 21 The number of TCR excision circles in a given sample was compared to a value obtained with 10-fold serial dilutions of an internal standard provided by Dr Daniel Douek (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD, USA).
Analysis of TCR Vb genes
Representatives of specific TCR Vb families were detected and quantified using quantitative PCR and flow cytometry (Coulter, Elite) as described previously. 21 
Results
Patient population and characteristics
Patients were classified according to the World Health Organization criteria. 22 Ten consecutive T þ CID patients were included in this study (Table 1) . Eight patients were male and two were female. Age of diagnosis ranged from 2 to 51 months with a mean age of 9.7 months (median of 5.7 months). The mean age at transplantation was 17.4 months (median of 11.75 months) with a range of 6-59 months.
Five of ten patients were diagnosed with Omenn's syndrome. One patient suffered from cartilage hair hypoplasia and four patients had mutations in the IL-2Rg gene (including two with the recurrent R222C mutation). 12 Seven of ten patients had a pulmonary infection before transplant, which is considered a poor prognostic factor, and three of them were very high-risk transplants. One patient (no. 6) received the BM infusion during his admission to the intensive care unit due to severe Pneumocystic jiroveci pneumonitis requiring prolonged mechanical ventilation. Prior to MUD transplant, one patient (no. 9) failed to engraft an MMRD BMT. Another patient (no. 7), who received an HLA identical MUD BMT, lost the graft within 4 weeks and underwent a second transplant obtained from the same donor following conditioning with CY and irradiation.
Immune evaluation prior to BMT Unlike the typical presentation of SCID, all patients had normal or elevated numbers of circulating lymphocytes ranging from 2500 to 66 500 cells/ml with CD3 þ T cells varying from 1600 to 61 180 cells/ml (Table 2) . In all patients, CD3
þ T cells were more than 1500/ml, whereas in three patients they were markedly increased, ranging from 6000 to 61 000 cells/ml ( Table 2 ). The number of circulating CD19 þ B cells was within normal limits in all patients but two who had markedly reduced peripheral B cells, while NK cells in peripheral blood appeared normal in all patients but one. Mitogenic responses to PHA varied widely from 0 to 139% of control samples ( Table 2) . Evaluation of T-cell repertoire showed that two patients had normal representation of all Vb families, while six other patients had restricted repertoire with oligoclonal expansion.
Humoral immunity was also variable among this group of patients. Four patients had low to undetectable levels of serum IgG, IgM or IgA, while two patients had normal Igs for their age. Two other patients had normal IgG with reduced IgM and/or IgA levels. Reduced IgG but normal IgA with reduced or normal IgM serum levels was also seen in two different patients. Antibody responses to tetanus toxoid and polio vaccines were invariably impaired in the seven patients who were tested.
Hematological engraftment
Neutrophil engraftment was achieved in all patients at a mean of 12.8 days (range, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] , including the patients who failed previous transplants (Table 3) . Engraftment of platelets was achieved within a mean of 23.1 days (range, 11-60 days). All 10 patients were free of red cell transfusions at a mean of 26 days (range, 11-46 days) after transplantation. In six patients, red cell blood group changed to donor type, indicating engraftment of donor erythoid lineage. In four cases, recipients and donors had identical blood groups. All patients demonstrated virtually 100% engraftment of donor lymphoid cells, without any evidence of residual recipient cells.
Immune reconstitution
As shown in Table 4 , 10 of the patients had consistently normal lymphocyte counts after immune suppression (GVHD prophylaxis) was discontinued. CD3 þ cells were also within normal limits ranging from 1333 to 3752 cells/ml (mean 2068). CD4 þ and CD8 þ T cells also reached normal limits ranging from 671 to 1503 cells/ml (mean 1030) and from 577 to 2255 cells/ml (mean 861), respectively. The number of circulating CD56 þ NK cells as well as CD19 þ B cells was also normal in all 10 patients.
In vitro T-cell mitogenic responses to PHA were normal in all patients. They ranged from 52 to 133% of control. Responses to anti-CD3 Ab were determined in only five patients and were better than those of controls (data not shown).
T-cell repertoire was assessed in six patients, which showed full representation of all Vb families tested. Further, analysis of thymic emigrants showed normal TCR excision circle levels in the eight patients tested.
Reconstitution of the humoral system was also robust with normal-for-age serum IgG, IgM and IgA levels in all 10 patients. Furthermore, Abs to tetanus toxoid were normal in all eight patients tested, as were Ab levels to polio vaccine.
Complications after BMT
During hospitalization, a total of seven episodes of fever were recorded for all patients (Table 5) . They all occurred within a few days after BMT, while patients were severely neutropenic. In three episodes, bacterial agents were recovered from blood cultures including Pseudomonas aeruginosa and Staphylococcus coagulase negative. Blood cultures obtained from patients during the rest of the febrile episodes failed to detect bacterial, fungal or viral infections. All patients recovered after administration of antibiotic therapy. Seven out of ten (70%) developed GVHD of grade II or more, which was reversed in all patients by using short courses of high-dose methylprednisolone.
Survival
All 10 patients are alive at 28-192 months after MUD BMT. Patients are well and are leading a normal life. Three patients continue to have short stature, one due to her condition of cartilage hair hypoplasia (no. 9), while in two others the cause of linear growth retardation remains under investigation.
Discussion
The best treatment for SCID remains BMT using an HLAidentical related donor. Unfortunately, for most patients with SCID or CID, such donors are rarely available and other solutions, such as MMRD or MUD BMT, have to be considered. We have studied the outcomes of 10 consecutive patients with T þ CID who received MUD BMT between 1989 and 2005 in a single center. This study, which reports the largest group of patients with T þ CID to have undergone MUD BMT, reveals a survival rate of 100% using this procedure, which is superior to 77-80.5% survival reported in MUD BMT for all types of SCID. 23, 24 Survival of SCID patients undergoing MMRD BMT has been reported to vary between 12.5 and 78% in single centers, while multicenter trials showed approximately 50% survival rate over the past two decades. 3, 18, 24, 25 The survival of T þ CID in these cohorts have been estimated to be even lower.
Our study shows that MUD BMT not only leads to a significant increase in survival of T þ CID, but also results in excellent long-term immune reconstitution. The ultimate purpose of BMT for these patients is to fully restore immune function and return patients to normal unrestricted lives indefinitely. All the patients with T þ CID who received a MUD transplant showed robust immune reconstitution. Humoral immunity was also completely reconstituted in all. Importantly, none of the long-term survivors had evidence of increased susceptibility to infections or malignancy.
There is no clear explanation for this excellent outcome of T þ CID after MUD BMT. Historically, protocols for MMRD BMT did not include conditioning schemes. Under such conditions, it is reasonable to assume that engraftment could be compromised, possibly leading to increased microbial colonization and infections. On the other hand, using MUD after conditioning offered rapid engraftment and, therefore, very low rates of infection, Table 2 Humoral and cell-mediated immunity at presentation which may reduce morbidity and increase survival of these patients. Perceived limitations of MUD BMT as a modality of treatment have consisted of a delay in treatment dictated by the time required to obtain BM and the concern of failing to identify a donor in the registries. 26 However, the latter concern has been greatly alleviated by the continuous expansion of the international unrelated donor base. [27] [28] [29] For all patients, we were able to find an acceptable donor in a timely fashion.
Contrary to common belief, we did not observe clinical deterioration while waiting for a transplant, which was another concern with MUD BMT. Further, no patient was lost because of such delay. On the contrary, we used this time to control infections and to improve patients' nutritional status, which are factors known to affect outcome. 30 Even among patients who required assisted ventilation prior to MUD BMT, we did not observe mortality. These results may challenge the instinct to rush to BMT while patients are clinically unstable, especially when myeloablation conditioning is required.
A major complication of BMT in SCID is life-threatening infections, especially of the lower respiratory tract. Indeed, interstitial pneumonitis is the most frequent cause of death in patients who received MMRD BMT. 24, 31 In contrast, we show here that on average T þ CID patients experienced only one major episode of infection or less while convalescing from MUD BMT.
A second significant threat to patients with SCID who receive transplants from donors other than related HLAidentical donor is GVHD. Between 45 and 85% of children are reported to develop acute GVHD following MUD BMT, despite various combinations of prophylactic treatments. 32, 33 Consistent with these data, 70% of the MUD BMT recipients in our series developed grade II or higher acute GVHD; however, it was transient and in most patients limited to the skin.
In conclusion, we have demonstrated that MUD is an excellent choice for BMT in T þ CID and is associated with long-term robust immune reconstitution, indicating that this mode of treatment should be preferred for patients with T þ CID when a related HLA-identical donor is not available. TCR 
